Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
Roberto MinaNisha S JosephJonathan L KaufmanVikas A GuptaLeonard T HeffnerCraig C HofmeisterLawrence H BoiseMadhav V DhodapkarCharise GleasonAjay K NookaSagar LonialPublished in: Cancer (2018)
The current data support the use of regimens combining novel agents in the upfront treatment of patients with pPCL as well as the role of ASCT and maintenance therapy for long-term disease control.